（文章来源：每日经济新闻） 先达股份（SH 603086，收盘价：10.25元）8月19日晚间发布公告称，公司第五届第六次董事会会议于 2025年8月19日以现场结合通讯表决方式召开。会议审议了《公司2025年半年度报告及其摘要的议案》 等文件。 2025年1至6月份，先达股份的营业收入构成为：除草剂占比91.69%，杀菌剂占比5.71%，中间体占比 1.85%，其他业务收入占比0.76%。 ...

Summary of Key Points Core Viewpoint - Jiangsu Fengshan Group Co., Ltd. held a half-year performance briefing on August 19, 2025, to discuss its financial results and future strategies, highlighting significant revenue growth and ongoing projects in the agricultural chemicals and new energy sectors [1][2]. Group 1: Financial Performance - For the first half of 2025, the company achieved a revenue of 619 million yuan, representing an increase of 18.74% year-on-year [4]. - The net profit attributable to shareholders was 30 million yuan, showing a substantial rise of 235.40% compared to the previous year, driven by a recovery in the pesticide industry and successful market expansion efforts [4]. Group 2: Product and Market Development - The company reported that its pesticide categories (insecticides, herbicides, and fungicides) have been performing well, with specific revenue contributions detailed in prior disclosures [3]. - The company is actively pursuing a "second growth curve" by exploring projects in new energy electrolyte and fine chemical new materials, alongside its established pesticide business [5][6]. Group 3: Project Updates - The Hubei project commenced trial production on January 8, 2025, with products already being sold in batches, indicating progress in operational plans [5]. - The Hubei project is expected to produce various chemical products, including ortho-chlorotoluene and its derivatives, which are essential for pharmaceuticals and agricultural chemicals [9][10]. Group 4: Strategic Direction - The company aims to enhance its pesticide, new energy electronic chemicals, and fine chemical new materials sectors, focusing on quality improvement, market demand alignment, and safety management [6]. - The company anticipates that the pesticide industry will continue to grow due to increasing global food demand, emphasizing the importance of innovation and international market expansion [7]. Group 5: Research and Development - Research and development investments are focused on innovations in pesticide production processes, new product formulations, and the development of new electrolyte products for sodium-ion and lithium-ion batteries [11].

Core Viewpoint - The company has demonstrated significant growth in revenue and net profit in the first half of 2025, driven by product optimization and market demand for its innovative agricultural solutions [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.423 billion yuan, representing a year-on-year increase of 11.82% [1]. - The net profit attributable to shareholders reached 136 million yuan, marking a substantial year-on-year growth of 2561.58% [1]. - The adjusted net profit after excluding non-recurring items was 131 million yuan, compared to a loss of 82,370 yuan in the same period last year [1]. Group 2: Product Development and Market Strategy - The company focuses on the research, production, and sales of environmentally friendly agricultural chemicals, with key products including herbicides and fungicides [2]. - The main product, Acetochlor, saw a significant price increase due to market supply and demand dynamics, leading to a substantial rise in gross profit margin [2]. - The newly launched product, Pyrazosulfuron-ethyl, has quickly gained market recognition as a herbicide for rice fields, contributing to the company's growth [2]. - The company is enhancing its competitive edge by optimizing traditional products and developing differentiated solutions for the wheat field herbicide market [2][3]. Group 3: Market Trends and Opportunities - The domestic agricultural chemical industry is showing signs of stabilization, with improvements in supply and demand dynamics [6]. - The price indices for herbicides, insecticides, and fungicides have shown moderate recovery, alleviating previous market imbalances [6]. - In the overseas market, the demand for agricultural chemicals is recovering, with significant year-on-year growth in export values for insecticides, fungicides, and herbicides [6]. - The company plans to leverage its innovative capabilities to enhance existing products and create a comprehensive industry layout to improve market competitiveness [6]. Group 4: Research and Development - The company has a robust pipeline of research projects, focusing on various crops and biotechnologies, aiming to commercialize a new compound every two years [7].

证券代码：300796 证券简称：贝斯美 公告编号：2025-065 绍兴贝斯美化工股份有限公司（以下简称"公司"）于2025年8月18日召开了第四 届董事会第九次会议、第四届监事会第六次会议，分别审议通过了《关于公司部分 募投项目延期的议案》，同意公司在募投项目实施主体、实施方式、建设内容、募 集资金投资用途及投资规模不发生变更的前提下，对首发部分募投项目达到预定可 使用状态的时间进行调整，该议案无需提交公司股东大会审议。现将具体情况公告 如下： 一、首发募集资金的基本情况 经中国证券监督管理委员会证监发行字[2019]1783号文核准，公司于2019年11月 向社会公开发行人民币普通股（A股）3,030万股，每股发行价为14.25元，应募集资 金总额为人民币43,177.50万元，根据有关规定扣除发行费用3,879.74万元后，实际募 集资金净额为39,297.76万元。该募集资金已于2019年11月到账。上述资金到账情况 业经容诚会计师事务所会验字[2019]7999号《验资报告》验证。公司对募集资金采 取了专户存储管理。 绍兴贝斯美化工股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、 ...

中泰证券股份有限公司 关于绍兴贝斯美化工股份有限公司 首发部分募投项目延期的核查意见 中泰证券股份有限公司（以下简称"保荐机构"）作为绍兴贝斯美化工股份 有限公司（以下简称"公司"）持续督导保荐机构，根据《证券发行上市保荐业 务管理办法》《深圳证券交易所创业板股票上市规则》《上市公司募集资金监管 规则》及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等法律法规的规定履行持续督导职责，对公司部分募投项目延期的 事项进行了核查，情况如下： 一、首发募集资金的基本情况 经中国证券监督管理委员会证监发行字[2019]1783 号文核准，公司于 2019 年 11 月向社会公开发行人民币普通股（A 股）3,030 万股，每股发行价为 14.25 元，应募集资金总额为人民币 43,177.50 万元，根据有关规定扣除发行费用 资报告》验证。公司对募集资金采取了专户存储管理。 二、首发募集资金使用与管理情况 截至 2025 年 6 月 30 日，公司首次公开发行股票募集资金投资项目及使用情 况如下： 拟投入金额 金金额 新建企业研发中心技改 项目 2 收购宁波捷力克 80%股 权3 注：1、公 ...

Core Insights - Company reported a revenue of 5.945 billion yuan for the first half of 2025, a year-on-year increase of 0.39%, and a net profit attributable to shareholders of 388 million yuan, a significant increase of 23.9% [1] - The company plans to distribute a cash dividend of 2 yuan per 10 shares, reflecting its commitment to shareholder returns [1] - The company has established a diversified structure with a focus on the health industry, covering five major sectors: pharmaceuticals, medical services, agrochemicals, new materials, and tourism [1] Pharmaceutical Sector - The company has strengthened its R&D investment, with several products receiving approvals, including the first generic version of calcipotriol betamethasone ointment, marking a significant breakthrough in psoriasis treatment [2] - The company is consolidating its prescription market advantage while actively expanding into domestic and overseas raw material markets, and has launched functional skincare products to enhance its product matrix [2] Medical Sector - The company has added new specialty clinics in its Chongqing Songshan Hospital, enhancing its medical service capabilities and achieving steady growth in consumer healthcare and health management [2] - The Beijing Huasheng Rehabilitation Hospital has increased its bed capacity to 457, with a steady rise in patient visits and solid progress in key rehabilitation disciplines [2] Agrochemical Sector - The agrochemical sector is experiencing a recovery in profitability due to improved supply-demand dynamics and price increases in certain product segments [3] - The company’s agrochemical business is stabilizing and contributing to overall performance growth [3] New Materials Sector - The new materials sector has seen an increase in orders and improved gross margins due to recovering demand and cost advantages [3] Tourism Sector - The tourism sector continues to show steady improvement, with the company actively seizing industry opportunities and enhancing market competitiveness [3] Strategic Focus - The company aims to continue developing a full industry chain model centered on "big health," integrating raw materials, formulations, functional skincare, health management, and medical services for sustainable long-term growth [3]

证券日报网讯 8月19日晚间，海利尔发布公告称，截至本公告日，公司及子公司对外担保金额为328， 100万元，占2024年12月31日公司经审计归属于上市公司股东的净资产的95.83%，全部为公司对子公司 提供的担保，无逾期担保。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 8月19日晚间，诺普信发布公告称，公司第七届董事会第七次会议审议通过了《关于2023 年限制性股票激励计划回购注销已不符合激励条件激励对象已获授但尚未解锁的限制性股票的议案》等 多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月19日晚间，诺普信发布公告称，公司第七届监事会第六次会议审议通过了《公司2025 年半年度报告及报告摘要的议案》等多项议案。 ...

Core Viewpoint - XianDa Co., Ltd. reported significant growth in its financial performance for the first half of 2025, with a notable increase in both revenue and net profit, driven by strategic initiatives and market conditions [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.423 billion yuan, representing a year-on-year increase of 11.82% [1] - The net profit attributable to shareholders reached 136 million yuan, marking a substantial year-on-year growth of 2561.58% [1] Industry Context - The domestic pesticide industry is stabilizing at a low level, with slight improvements in supply and demand dynamics [1] - The overseas market inventory is gradually returning to normal levels, and the pesticide export market continues to show signs of recovery [1] Strategic Initiatives - The company is implementing a dual-driven strategy of "innovation-driven" and "technical services," focusing on four key areas: product research and development, product industrialization, enhancement of domestic marketing capabilities, and expansion into overseas markets [1] - The main product, Acetochlor, saw a significant price increase due to market supply and demand factors, which positively impacted the product's gross margin [1] - The successful market launch of the innovative product Pyrazosulfuron-ethyl has injected new momentum into the company's performance growth [1] R&D and Competitive Advantage - Since its establishment, the company has focused on high-end herbicides and maintained high levels of R&D investment, developing proprietary patented products [1] - The company has built a product portfolio of proprietary chemical compounds, enhancing its core competitiveness [1] - Over 20 years of development, the company has mastered the full industrial chain capabilities for creating chemical compounds [1]